---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027327"
form_type: "8-K"
ticker: "EXOZ"
cik: "0002010788"
company_name: "EXOZYMES INC."
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:24:23.576897+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# eXoZymes achieves 100× scale-up of NCT production with >99% feedstock conversion

## Summary
- Scaled NCT production 100-fold using proprietary exozyme cell-free platform, achieving >99% conversion from feedstock to product.
- Batch executed under partner-operated conditions by Cayman Chemical, demonstrating process robustness and transferability.
- CEO Michael Heltzen calls milestone an inflection point for cell-free enzyme-driven biomanufacturing.
- Additional technical details and NCT extraction results expected in early 2026 after downstream analysis.

## SEC filing metadata
- accession: 0001493152-25-027327
- form_type: 8-K
- ticker: EXOZ
- cik: 0002010788
- company_name: EXOZYMES INC.
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2010788/000149315225027327/0001493152-25-027327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2010788/000149315225027327/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027327
- JSON: https://secwatch.observer/filing/0001493152-25-027327.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027327.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.